Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:48 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Gabapentin for the Reduction of Opiate Use Following Pulmonary Resection (GROUP Trial)
NCT05100160 · M.D. Anderson Cancer Center · PHASE3 · withdrawn · last registry update 2023-04-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “0 patient accrual” | – | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CACNA1H within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-04-02Results posted on the registry: Henry Ford Health System, Celecoxib + Ketorolac (NCT03818919)
- 2024-03-21Results posted on the registry: Indiana University, Gabapentin (NCT05172570)
- 2024-03-21Also stopped (terminated): Indiana University, Gabapentin (NCT05172570)
- 2024-02-14Results posted on the registry: AppliedVR Inc., multi-modality pain management (NCT04010266)
- 2024-01-31Results posted on the registry: Vanderbilt University Medical Center, Opioid Analgesic + Opioid-Free Postoperative Pain Regimen (NCT04990804)
- 2024-01-31Also stopped (terminated): Vanderbilt University Medical Center, Opioid Analgesic + Opioid-Free Postoperative Pain Regimen (NCT04990804)
- 2024-01-09Results posted on the registry: The Cleveland Clinic, Gabapentin enacarbil + Placebo (NCT02840240)
- 2024-01-03Results posted on the registry: Arbor Pharmaceuticals, Inc., Placebo + Alprazolam 2 mg (NCT06097676)
- 2023-12-28Also stopped (terminated): University of Texas Southwestern Medical Center, a drug against CACNA1H (NCT04558840)
- 2023-12-18Results posted on the registry: Cedars-Sinai Medical Center, ERAS + Standard of care (NCT03738904)
- 2023-12-13Results posted on the registry: Medical University of South Carolina, N-Acetylcysteine + Gabapentin (NCT03220776)
- 2023-12-06Results posted on the registry: Viatris Specialty LLC, gabapentin 600 mg + gabapentin 1200 mg (NCT04570436)
- 2023-10-25Also stopped (withdrawn): Massachusetts General Hospital, buprenorphine transdermal delivery system (BTDS) + Placebo for BTDS patch (NCT02138357)
- 2023-10-18Results posted on the registry: Weill Medical College of Cornell University, Gabapentin + Placebo (NCT04230980)
- 2023-10-05Also stopped (terminated): London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, a drug against CACNA1H (NCT03500744)
- 2023-10-04Results posted on the registry: Wake Forest University Health Sciences, Gabapentin + Placebo (NCT02685735)
- 2023-08-14Results posted on the registry: Viatris Specialty LLC, gabapentin 600 mg + gabapentin 1200 mg (NCT05319756)
- 2023-08-01Results posted on the registry: State University of New York at Buffalo, Gabapentin + Acetaminophen (NCT04429022)
- 2023-07-28Phase 3 first posted: University of Miami, Acetaminophen + Celebrex (NCT05965492)
- 2023-06-27Phase 3 first posted: Tanta University, Baclofen 10mg + Gabapentin (NCT05921604)
- 2023-04-27Results posted on the registry: Medical College of Wisconsin, Methadone + Morphine (NCT02558010)
- 2023-04-24Phase 3 first posted: Yale University, Naltrexone Pill + Naltrexone Injection (NCT05827159)
- 2023-04-21Results posted on the registry: The University of Texas Health Science Center, Houston, Ketamine plus usual care + Usual Care (NCT04129086)
- 2023-01-26Also stopped (withdrawn): Massachusetts General Hospital, Gabapentin + Placebo (NCT02957097)
- 2022-12-21Phase 3 first posted: Jocelyn Fitzgerald, Multimodal Bundle Drugs + Bladder Instillation (NCT05658874)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision